NeuroDawn Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
100
- Latest Deal Type
-
Series C
- Investors
-
15
NeuroDawn General Information
Description
Developer of central nervous system drugs designed to treat neurological diseases. The company utilizes an internal research and development platform integrating chemical synthesis, biological screening, chemistry, manufacturing and control development, drug metabolism and pharmacokinetics research, in vivo pharmacology research, and toxicology research, enabling medical professionals to treat patients with strokes, alzheimer's disease, and neuropathic pain.
Contact Information
Website
www.neurodawn.cnCorporate Office
- Building A3, Tianyin Health Innovation Park
- Number 2222 Gezhi Road, Jiangning District
- Nanjing, Jiangsu 210000
- China
Corporate Office
- Building A3, Tianyin Health Innovation Park
- Number 2222 Gezhi Road, Jiangning District
- Nanjing, Jiangsu 210000
- China
NeuroDawn Timeline
NeuroDawn Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series C) | 31-Oct-2024 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 30-Sep-2024 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series B1) | 12-Jan-2024 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 10-Nov-2023 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A1) | 06-Feb-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 22-Jul-2022 | $10.8M | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 12-Aug-2021 | $10.8M | $10.8M | Completed | Generating Revenue |
NeuroDawn Signals
NeuroDawn Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Beijing Shengshi Hongming Investment Fund Management | Fund of Funds | Minority | ||
| Nanjing Innovation Capital Group | Venture Capital | Minority | ||
| Nanjing Jiangning Science and Technology Venture Capital Group | Government | Minority | ||
| Fuzhou Rongtou Investment | Government | Minority | ||
| Chunxin Capital | Venture Capital | Minority |
NeuroDawn Investments (1)
NeuroDawn’s most recent deal was a Corporate with Ruichu. The deal was made on 14-Oct-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ruichu | 14-Oct-2021 | Corporate | Drug Discovery |
NeuroDawn FAQs
-
When was NeuroDawn founded?
NeuroDawn was founded in 2020.
-
Where is NeuroDawn headquartered?
NeuroDawn is headquartered in Nanjing, China.
-
What is the size of NeuroDawn?
NeuroDawn has 100 total employees.
-
What industry is NeuroDawn in?
NeuroDawn’s primary industry is Drug Discovery.
-
Is NeuroDawn a private or public company?
NeuroDawn is a Private company.
-
What is NeuroDawn’s current revenue?
The current revenue for NeuroDawn is .
-
How much funding has NeuroDawn raised over time?
NeuroDawn has raised $53.7M.
-
Who are NeuroDawn’s investors?
Beijing Shengshi Hongming Investment Fund Management, Nanjing Innovation Capital Group, Nanjing Jiangning Science and Technology Venture Capital Group, Fuzhou Rongtou Investment, and Chunxin Capital are 5 of 15 investors who have invested in NeuroDawn.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process